These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 39304979)

  • 1. Tetrabenazine, a vesicular monoamine transporter 2 inhibitor, inhibits vesicular storage capacity and release of monoamine transmitters in mouse brain tissue.
    Tod P; Varga A; Román V; Lendvai B; Pálkovács R; Sperlágh B; Vizi ES
    Br J Pharmacol; 2024 Sep; ():. PubMed ID: 39304979
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The vesicular monoamine transporter (VMAT-2) inhibitor tetrabenazine induces tremulous jaw movements in rodents: implications for pharmacological models of parkinsonian tremor.
    Podurgiel SJ; Nunes EJ; Yohn SE; Barber J; Thompson A; Milligan M; Lee CA; López-Cruz L; Pardo M; Valverde O; Lendent C; Baqi Y; Müller CE; Correa M; Salamone JD
    Neuroscience; 2013 Oct; 250():507-19. PubMed ID: 23867769
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The MAO-B inhibitor deprenyl reduces the oral tremor and the dopamine depletion induced by the VMAT-2 inhibitor tetrabenazine.
    Podurgiel SJ; Yohn SE; Dortche K; Correa M; Salamone JD
    Behav Brain Res; 2016 Feb; 298(Pt B):188-91. PubMed ID: 26590367
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tetrabenazine Mitigates Aberrant Release and Clearance of Dopamine in the Nigrostriatal System, and Alleviates L-DOPA-Induced Dyskinesia in a Mouse Model of Parkinson's Disease.
    Tseng KY; Kuo TT; Wang V; Huang EY; Ma KH; Olson L; Hoffer BJ; Chen YH
    J Parkinsons Dis; 2022; 12(5):1545-1565. PubMed ID: 35599497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tetrabenazine inhibition of monoamine uptake and methamphetamine behavioral effects: locomotor activity, drug discrimination and self-administration.
    Meyer AC; Horton DB; Neugebauer NM; Wooters TE; Nickell JR; Dwoskin LP; Bardo MT
    Neuropharmacology; 2011 Sep; 61(4):849-56. PubMed ID: 21669212
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tetrabenazine for the treatment of hyperkinetic movement disorders: a review of the literature.
    Chen JJ; Ondo WG; Dashtipour K; Swope DM
    Clin Ther; 2012 Jul; 34(7):1487-504. PubMed ID: 22749259
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Not All Antidepressants Are Created Equal: Differential Effects of Monoamine Uptake Inhibitors on Effort-Related Choice Behavior.
    Yohn SE; Collins SL; Contreras-Mora HM; Errante EL; Rowland MA; Correa M; Salamone JD
    Neuropsychopharmacology; 2016 Feb; 41(3):686-94. PubMed ID: 26105139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetrabenazine, a vesicular monoamine transporter-2 inhibitor, attenuates morphine-induced hyperlocomotion in mice through alteration of dopamine and 5-hydroxytryptamine turnover in the cerebral cortex.
    Kitanaka N; Kitanaka J; Hall FS; Kandori T; Murakami A; Muratani K; Nakano T; Uhl GR; Takemura M
    Pharmacol Biochem Behav; 2018 Sep; 172():9-16. PubMed ID: 30017858
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of [11C]tetrabenazine as an in vivo radioligand for the vesicular monoamine transporter.
    DaSilva JN; Carey JE; Sherman PS; Pisani TJ; Kilbourn MR
    Nucl Med Biol; 1994 Feb; 21(2):151-6. PubMed ID: 9234277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Identification of conformationally sensitive residues essential for inhibition of vesicular monoamine transport by the noncompetitive inhibitor tetrabenazine.
    Ugolev Y; Segal T; Yaffe D; Gros Y; Schuldiner S
    J Biol Chem; 2013 Nov; 288(45):32160-32171. PubMed ID: 24062308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrabenazine Facilitates Exocytosis by Enhancing Calcium-Induced Calcium Release through Ryanodine Receptors.
    de Pascual R; Álvarez-Ortego N; de Los Ríos C; Jacob-Mazariego G; García AG
    J Pharmacol Exp Ther; 2019 Oct; 371(1):219-230. PubMed ID: 31209099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Methylenedioxymethamphetamine decreases plasmalemmal and vesicular dopamine transport: mechanisms and implications for neurotoxicity.
    Hansen JP; Riddle EL; Sandoval V; Brown JM; Gibb JW; Hanson GR; Fleckenstein AE
    J Pharmacol Exp Ther; 2002 Mar; 300(3):1093-100. PubMed ID: 11861820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of NBI-98782, a selective vesicular monoamine transporter 2 (VMAT2) inhibitor, on neurotransmitter efflux and phencyclidine-induced locomotor activity: Relevance to tardive dyskinesia and antipsychotic action.
    Huang M; He W; Rajagopal L; Kudwa A; Grigoriadis DE; Meltzer HY
    Pharmacol Biochem Behav; 2020 Mar; 190():172872. PubMed ID: 32084491
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders.
    Jankovic J; Clarence-Smith K
    Expert Rev Neurother; 2011 Nov; 11(11):1509-23. PubMed ID: 22014129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Role of vesicular monoamine transporter type 2 in rodent insulin secretion and glucose metabolism revealed by its specific antagonist tetrabenazine.
    Raffo A; Hancock K; Polito T; Xie Y; Andan G; Witkowski P; Hardy M; Barba P; Ferrara C; Maffei A; Freeby M; Goland R; Leibel RL; Sweet IR; Harris PE
    J Endocrinol; 2008 Jul; 198(1):41-9. PubMed ID: 18577569
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of tetrabenazine on methamphetamine-induced hyperactivity in mice are dependent on order and time-course of administration.
    Kuribara H
    Pharmacol Biochem Behav; 1997 Jan; 56(1):9-14. PubMed ID: 8981603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The profile of mephedrone on human monoamine transporters differs from 3,4-methylenedioxymethamphetamine primarily by lower potency at the vesicular monoamine transporter.
    Pifl C; Reither H; Hornykiewicz O
    Eur J Pharmacol; 2015 May; 755():119-26. PubMed ID: 25771452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluoxetine Administration Exacerbates Oral Tremor and Striatal Dopamine Depletion in a Rodent Pharmacological Model of Parkinsonism.
    Podurgiel SJ; Milligan MN; Yohn SE; Purcell LJ; Contreras-Mora HM; Correa M; Salamone JD
    Neuropsychopharmacology; 2015 Aug; 40(9):2240-7. PubMed ID: 25759301
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.
    Nair SG; Gudelsky GA
    Psychopharmacology (Berl); 2006 Jan; 184(2):182-9. PubMed ID: 16378215
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The dopamine depleting agent tetrabenazine alters effort-related decision making as assessed by mouse touchscreen procedures.
    Yang JH; Presby RE; Rotolo RA; Quiles T; Okifo K; Zorda E; Fitch RH; Correa M; Salamone JD
    Psychopharmacology (Berl); 2020 Sep; 237(9):2845-2854. PubMed ID: 32561947
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.